Cash rich Pfizer (NYSE: PFE) has completed its $11.6 billion acquisition of Biohaven Pharmaceutical, including its money-making calcitonin gene-related peptide 5 October 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news